Company intelligence / Profile preview

Othera Pharmaceuticals, Inc.

Exton, Pennsylvania, USAlinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Completed Phase 2 trial of OT-551 for geographic atrophy (an advanced form of dry AMD) with positive interim results announced in April 2009. Also conducted Phase 1/2 evaluation of OT-730 ophthalmic solution for reducing intraocular pressure in subjects with ocular hypertension or open-angle glaucoma.

Therapeutic areas: OphthalmologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

OT-551

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Othera Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Othera Pharmaceuticals, Inc..

Explore the full profile